Matches in SemOpenAlex for { <https://semopenalex.org/work/W98290650> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W98290650 endingPage "40" @default.
- W98290650 startingPage "237" @default.
- W98290650 abstract "To observe beneficial effects of somatostatin analogues in terms of time taken by the enterocutaneous fistula to close, total hospital stay, cost of treatment and mortality.A comparative study.The study was carried out from 01-10-1999 to 30-09-2002 in Surgical Units of Bahawal Victoria Hospital, Bahawalpur.In this study 33 patients were distributed randomly in two groups. Both groups were almost similar in terms of age, sex, anatomical location and cause of enterocutaneous fistulae. In group-A, 17 patients were treated by conventional methods (nil per orum, total parenteral nutrition, antibiotics, skin and wound care and control of sepsis). While in group-B, 16 patients were treated by long acting somatostatin analogue (Sandostatin 300 microgram subcutaneously /day in three divided doses) in addition to the conventional treatment.Of the 33 patients studied, 52% enterocutaneous fistulae were arising from ileum, 18% from jejunum, 12% from colon, 9% from biliary tree/pancreas, 6% from duodenum, and 3% from appendix. Low output fistulae (less than 200 ml/24 hour) were 24.24% in group A and 18.18% in group-B. Moderate output fistulae were 15.15% and 21.21% respectively. High output fistulae (>500 ml/ 24 hours) were 12.12% and 9.10% respectively. Etiologically, 85% were post-operative, 9% traumatic, 3% tuberculous and 3% due to inflammatory bowel disease. Fifty-two percent patients having fistula were malnourished, and 60% were anemic. In group-B with somatostatin the fistula closure time and hospital stay were marginally decreased, which was statistically insignificant. The cost of treatment was statistically significant in same group. In all the 33 patients studied, fistula closed except in 5 who expired. Mortality was not affected by the use of somatostatin.Somatostatin and its analogues can be used to decrease fistula output, thus making enterocutaneous fistulae easy to manage in terms of fluid and electrolytes and protein imbalances. Somatostatin and its analogues have shown some beneficial effects with regard to fistula closure rate and hospital stay, but the effects are statistically insignificant. There was significant increase in the cost of treatment. Thus the role of somatostatin is not established in the closure of enterocutaneous fistula." @default.
- W98290650 created "2016-06-24" @default.
- W98290650 creator A5010533430 @default.
- W98290650 creator A5033316002 @default.
- W98290650 creator A5061705971 @default.
- W98290650 date "2004-04-01" @default.
- W98290650 modified "2023-09-23" @default.
- W98290650 title "Role of somatostatin analogues in the management of enterocutaneous fistulae." @default.
- W98290650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15228830" @default.
- W98290650 hasPublicationYear "2004" @default.
- W98290650 type Work @default.
- W98290650 sameAs 98290650 @default.
- W98290650 citedByCount "11" @default.
- W98290650 countsByYear W982906502013 @default.
- W98290650 countsByYear W982906502016 @default.
- W98290650 countsByYear W982906502017 @default.
- W98290650 countsByYear W982906502020 @default.
- W98290650 crossrefType "journal-article" @default.
- W98290650 hasAuthorship W98290650A5010533430 @default.
- W98290650 hasAuthorship W98290650A5033316002 @default.
- W98290650 hasAuthorship W98290650A5061705971 @default.
- W98290650 hasConcept C126322002 @default.
- W98290650 hasConcept C141071460 @default.
- W98290650 hasConcept C2776297358 @default.
- W98290650 hasConcept C2776341189 @default.
- W98290650 hasConcept C2777785397 @default.
- W98290650 hasConcept C2778384902 @default.
- W98290650 hasConcept C2779105634 @default.
- W98290650 hasConcept C2780678043 @default.
- W98290650 hasConcept C71924100 @default.
- W98290650 hasConcept C78722104 @default.
- W98290650 hasConcept C90924648 @default.
- W98290650 hasConceptScore W98290650C126322002 @default.
- W98290650 hasConceptScore W98290650C141071460 @default.
- W98290650 hasConceptScore W98290650C2776297358 @default.
- W98290650 hasConceptScore W98290650C2776341189 @default.
- W98290650 hasConceptScore W98290650C2777785397 @default.
- W98290650 hasConceptScore W98290650C2778384902 @default.
- W98290650 hasConceptScore W98290650C2779105634 @default.
- W98290650 hasConceptScore W98290650C2780678043 @default.
- W98290650 hasConceptScore W98290650C71924100 @default.
- W98290650 hasConceptScore W98290650C78722104 @default.
- W98290650 hasConceptScore W98290650C90924648 @default.
- W98290650 hasIssue "4" @default.
- W98290650 hasLocation W982906501 @default.
- W98290650 hasOpenAccess W98290650 @default.
- W98290650 hasPrimaryLocation W982906501 @default.
- W98290650 hasRelatedWork W130027888 @default.
- W98290650 hasRelatedWork W1965153960 @default.
- W98290650 hasRelatedWork W1986329037 @default.
- W98290650 hasRelatedWork W1994215581 @default.
- W98290650 hasRelatedWork W1996622508 @default.
- W98290650 hasRelatedWork W1999213446 @default.
- W98290650 hasRelatedWork W2014874961 @default.
- W98290650 hasRelatedWork W2018596338 @default.
- W98290650 hasRelatedWork W2028710508 @default.
- W98290650 hasRelatedWork W2030738368 @default.
- W98290650 hasRelatedWork W2031347789 @default.
- W98290650 hasRelatedWork W2037369414 @default.
- W98290650 hasRelatedWork W2040762685 @default.
- W98290650 hasRelatedWork W206002565 @default.
- W98290650 hasRelatedWork W2077691782 @default.
- W98290650 hasRelatedWork W2118099086 @default.
- W98290650 hasRelatedWork W2170892464 @default.
- W98290650 hasRelatedWork W2332061100 @default.
- W98290650 hasRelatedWork W40954131 @default.
- W98290650 hasRelatedWork W45384918 @default.
- W98290650 hasVolume "14" @default.
- W98290650 isParatext "false" @default.
- W98290650 isRetracted "false" @default.
- W98290650 magId "98290650" @default.
- W98290650 workType "article" @default.